• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 15, 2018

View Archived Issues

Janssen wins FDA approval for significant new prostate cancer drug

At least six weeks ahead of its assigned PDUFA date, Janssen Research & Development LLC's apalutamide has become the first FDA-approved therapy to treat patients with non-metastatic castration-resistant prostate cancer (nmCRPC), those whose disease has quit responding to medical or surgical treatments that lower testosterone but has yet to spread. Read More

Reimagining HHS will be easier said than done

In his second week on the job, Health and Human Services (HHS) Secretary Alex Azar got a crash course on why it's easier to imagine changes to 50-year-old U.S. government programs like Medicaid than it is to make them happen. Read More

Galmed shares tumble on phase IIa Aramchol trial read-out

A mid-stage trial testing the Galmed Pharmaceuticals Ltd. candidate aramchol (arachidyl amido cholanoic acid) over 12 weeks found it made no apparent difference in liver fat for people with HIV-associated lipodystrophy and non-alcoholic fatty liver disease (NAFLD). While company shares (NASDAQ:GLMD) fell by 45.4 percent on the news, Galmed's chief scientific officer, Liat Hayardeny, told BioWorld that substantial differences in the pathogenesis of fatty liver in HIV and non-alcoholic steatohepatitis (NASH) – the focus of another aramchol trial due to read out next quarter – should quell concerns about any potential read-through. Read More

Tetraphase cUTI bid fails while agency mulls NDA

Inadequately concentrated drug may have caused Tetraphase Pharmaceuticals Inc.'s topline phase III blowup with intravenous (I.V.) eravacycline in complicated urinary tract infections (cUTI), and the company said the results bear no read-through to the same compound's value in complicated intra-abdominal infections (cIAI), for which it's under review in the U.S. and Europe. Read More

Santen reports promising early data from carotuximab phase I/II study

HONG KONG – Japan's Santen Inc. disclosed positive top line results from the phase I/II study of its carotuximab candidate, DE-122, for the treatment of wet age-related macular degeneration (AMD). Read More

The PD-1/PD-L1 antibody race in China is on

HONG KONG – Talks of China's market for PD-1/PD-L1 antibodies got even more heated after the CFDA issued guidelines for the submission of new drug applications (NDA) for immunotherapy antibodies last week. Read More

GWAS in Chinese population implicates immune system in Alzheimer's disease

A study has identified common genetic variants in the Chinese population contributing to the risk of developing Alzheimer's disease (AD) that possibly exert functional effects through the immune system, which could have important implications for AD management. Read More

Financings

Elanix Biotechnologies AG, of Berlin, Germany, a developer of tissue regeneration products and specialty cosmetics in the field of dermatology and gynecology, said it raised €1.125 million (US$1.39 million) from the sale of 300,019 shares at €3.75 each.  Read More

Earnings

Intercept Pharmaceuticals Inc., of New York, reported that it recorded $129.2 million of worldwide net Ocaliva (obeticholic acid) sales for the full year and $37.3 million for the fourth quarter of 2017. Read More

Other news to note

Scythian Biosciences Corp., of Toronto, said it received approval to list its common shares on the Nasdaq Capital Market. The shares will begin trading on Feb. 22 under the ticker SCYB. Read More

In the clinic

Merck & Co. Inc., of Kenilworth, N.J., said it will be stopping protocol 019, also known as the APECS study, a phase III trial evaluating verubecestat (MK-8931), a small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), in people with prodromal Alzheimer's disease. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe